Does increasing model complexity improve HEART-based chest pain risk stratification? A multicentre development and held-out emergency department validation study
Abstract
Background and objectives: The History, ECG, Age, Risk factors and Troponin (HEART) score is widely used for emergency department (ED) chest pain risk stratification, but its fixed-point structure may not optimally represent relationships between its components and major adverse cardiac events (MACE). We evaluated whether increasingly flexible modelling approaches improve prediction when restricted to the same five HEART components.
Methods: We conducted a retrospective multicentre cohort study of 47 853 adult ED patients with chest pain and documented HEART scores across six EDs from 2021 to 2023. Data from five EDs (n=39 587) were used for model development and one geographically held-out ED (n=8266) was used for validation. The conventional HEART score was compared with categorical cross-validated logistic regression (CVLR) and extreme gradient boosting (XGBoost) for predicting 30-day MACE. Performance was assessed using the area under the receiver operating characteristic (AUROC), the area under the precision-recall curve (AUPRC), the Brier score, paired bootstrap comparisons and clinical performance at comparable-sensitivity operating points.
Results: In the held-out validation cohort, 267 patients (3.23%) experienced 30-day MACE. AUROCs were similar for HEART (0.855), CVLR (0.857) and XGBoost (0.856; pairwise p>0.05). In contrast, both data-driven models demonstrated significantly higher AUPRC than HEART: CVLR (0.237 vs 0.187; Δ=0.050, p<0.001) and XGBoost (0.244 vs…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 8,266 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.